Associated Genetic Biomarkers

Overview

NCI Definition: An acute myeloid leukemia secondary to a myelodysplastic syndrome or therapy-related. (WHO, 2001) [1]

Significant Genes in Secondary Acute Myeloid Leukemia

ABL1 +

ABL2 +

AFF1 +

ASXL1 +

BCOR +

BCR +

CALR +

CBFB +

CBL +

CREBBP +

CRLF2 +

CSF1R +

DEK +

ELL +

EPOR +

ETV6 +

EZH2 +

FLT3 +

HIP1 +

HRAS +

IDH1 +

IDH2 +

IL7R +

JAK1 +

JAK2 +

JAK3 +

KIT +

KMT2A +

KRAS +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MPL +

MYH11 +

NF1 +

NPM1 +

NRAS +

NUP214 +

PBX1 +

PDGFRB +

PRDM16 +

PTPN11 +

RIT1 +

RPN1 +

RUNX1 +

RUNX1T1 +

SF3B1 +

SH2B3 +

SRSF2 +

STAG2 +

TCF3 +

TP53 +

U2AF1 +

ZRSR2 +

Disease Details

Synonyms
Secondary Acute Granulocytic Leukemia, Secondary AML, Secondary Acute Myelocytic Leukemia, Secondary Acute Myeloid Leukemia (AML), Secondary Acute Myelogenous Leukemia, Secondary Acute Myeloblastic Leukemia, Secondary AGL
Parent(s)
Secondary Malignant Neoplasm
Children
Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome and Therapy-Related Acute Myeloid Leukemia

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.